{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:06:13Z","timestamp":1786118773909,"version":"build-2736575974"},"reference-count":45,"publisher":"Ovid Technologies (Wolters Kluwer Health)","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2007,8]]},"DOI":"10.1097\/blo.0b013e3180986d60","type":"journal-article","created":{"date-parts":[[2007,5,18]],"date-time":"2007-05-18T17:55:24Z","timestamp":1179510924000},"page":"40-43","source":"Crossref","is-referenced-by-count":29,"title":["Linezolid in the Treatment of Implant-related Chronic Osteomyelitis"],"prefix":"10.1097","volume":"461","author":[{"given":"Michael","family":"Vercillo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J","family":"Patzakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Holtom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charalampos G","family":"Zalavras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-12-20210317","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1053\/jinf.2001.0863","article-title":"Linezolid treatment of prosthetic hip infections due to methicillin-resistant Staphylococcus aureus (MRSA).","volume":"43","author":"Bassetti","year":"2001","journal-title":"J Infect"},{"key":"R2-12-20210317","first-page":"505","article-title":"Treatment of multifocal vancomycin-resistant Enterococcus faecium osteomyelitis in sickle cell disease: a preliminary report.","volume":"32","author":"Bibbo","year":"2003","journal-title":"Am J Orthop"},{"key":"R3-12-20210317","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1086\/345744","article-title":"Linezolid for the treatment of multidrug-resistant, gram-positive infections: experience from a compassionate-use program.","volume":"36","author":"Birmingham","year":"2003","journal-title":"Clin Infect Dis"},{"key":"R4-12-20210317","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1128\/AAC.50.4.1599-1602.2006","article-title":"Good clinical outcomes but high rates of adverse reactions during linezolid therapy for serious infections: a proposed protocol for monitoring therapy in complex patients.","volume":"50","author":"Bishop","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"R5-12-20210317","first-page":"624","article-title":"Reduced susceptibility of Staphylococcus aureus to vancomycin-Japan, 1996.","volume":"46","year":"1997","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"R6-12-20210317","first-page":"813","article-title":"Update: Staphylococcus aureus with reduced susceptibility to vancomycin-United States, 1997.","volume":"46","year":"1997","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"R7-12-20210317","first-page":"1165","article-title":"Staphylococcus aureus with reduced susceptibility to vancomycin-Illinois, 1999.","volume":"48","year":"2000","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"R8-12-20210317","first-page":"565","article-title":"Staphylococcus aureus resistant to vancomycin-United States, 2002.","volume":"51","year":"2002","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"R9-12-20210317","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1056\/NEJMoa025025","article-title":"Vancomycin-Resistant Staphylococcus aureus Investigative Team. Infection with vancomycin-resistant Staphylococcus aureus containing the vanA resistance gene.","volume":"348","author":"Chang","year":"2003","journal-title":"N Engl J Med"},{"key":"R10-12-20210317","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1086\/381093","article-title":"Clinical features associated with bacteremia due to heterogeneous vancomycin-intermediate Staphylococcus aureus.","volume":"38","author":"Charles","year":"2004","journal-title":"Clin Infect Dis"},{"key":"R11-12-20210317","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1097\/01.blo.0000088564.81746.62","article-title":"A clinical staging system for adult osteomyelitis.","volume":"414","author":"Cierny","year":"2003","journal-title":"Clin Orthop Relat Res"},{"key":"R12-12-20210317","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1097\/00003086-200508000-00003","article-title":"Biofilm theory can guide the treatment of device-related orthopaedic infections.","volume":"437","author":"Costerton","year":"2005","journal-title":"Clin Orthop Relat Res"},{"key":"R13-12-20210317","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1177\/039139880502801103","article-title":"Biofilm in implant infections: its production and regulation.","volume":"28","author":"Costerton","year":"2005","journal-title":"Int J Artif Organs"},{"key":"R14-12-20210317","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.1016\/S0140-6736(01)06964-1","article-title":"Oxazolidinone antibiotics.","volume":"358","author":"Diekema","year":"2001","journal-title":"Lancet"},{"key":"R15-12-20210317","doi-asserted-by":"crossref","first-page":"2597","DOI":"10.1002\/(SICI)1097-0142(19981215)83:12<2597::AID-CNCR27>3.0.CO;2-L","article-title":"Mississippi mud in the 1990s: risks and outcomes of vancomycin-associated toxicity in general oncology practice.","volume":"83","author":"Elting","year":"1998","journal-title":"Cancer"},{"key":"R16-12-20210317","doi-asserted-by":"crossref","first-page":"2723","DOI":"10.1128\/AAC.46.8.2723-2726.2002","article-title":"Hematologic effects of linezolid: summary of clinical experience.","volume":"46","author":"Gerson","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"key":"R17-12-20210317","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1001\/jama.285.10.1291","article-title":"Linezolid and reversible myelosuppression.","volume":"285","author":"Green","year":"2001","journal-title":"JAMA"},{"key":"R18-12-20210317","doi-asserted-by":"crossref","first-page":"264","DOI":"10.2106\/00004623-198567020-00014","article-title":"Bacterial adherence to biomaterials and tissue. The significance of its role in clinical sepsis.","volume":"67","author":"Gristina","year":"1985","journal-title":"J Bone Joint Surg Am"},{"key":"R19-12-20210317","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1517\/14740338.3.5.405","article-title":"The safety and efficacy of linezolid in orthopaedic practice for the treatment of infection due to antibiotic-resistant organisms.","volume":"3","author":"Harwood","year":"2004","journal-title":"Expert Opin Drug Saf"},{"key":"R20-12-20210317","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1093\/jac\/40.1.135","article-title":"Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility.","volume":"40","author":"Hiramatsu","year":"1997","journal-title":"J Antimicrob Chemother"},{"key":"R21-12-20210317","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1097\/00003086-200210000-00007","article-title":"Osteomyelitis attributable to vancomycin-resistant enterococci.","volume":"403","author":"Holtom","year":"2002","journal-title":"Clin Orthop Relat Res"},{"key":"R23-12-20210317","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1086\/381202","article-title":"Treatment outcomes for serious infections caused by methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility.","volume":"38","author":"Howden","year":"2004","journal-title":"Clin Infect Dis"},{"key":"R24-12-20210317","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1086\/499367","article-title":"Changes in the epidemiology of methicillin-resistant Staphylococcus aureus in intensive care units in US hospitals, 1992-2003.","volume":"42","author":"Klevens","year":"2006","journal-title":"Clin Infect Dis"},{"key":"R25-12-20210317","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1086\/379012","article-title":"Linezolid-associated toxic optic neuropathy: a report of 2 cases.","volume":"37","author":"Lee","year":"2003","journal-title":"Clin Infect Dis"},{"key":"R26-12-20210317","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1056\/NEJM199704033361406","article-title":"Osteomyelitis.","volume":"336","author":"Lew","year":"1997","journal-title":"NEngl J Med"},{"key":"R27-12-20210317","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1592\/phco.21.3.263.34198","article-title":"Comparison of length of hospital stay for patients with known or suspected methicillin-resistant Staphylococcus species infections treated with linezolid or vancomycin: a randomized, multicenter trial.","volume":"21","author":"Li","year":"2001","journal-title":"Pharmacotherapy"},{"key":"R28-12-20210317","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1093\/jac\/46.3.347","article-title":"Quinupristin\/dalfopristin and linezolid: where, when, which and whether to use?","volume":"46","author":"Livermore","year":"2000","journal-title":"J Antimicrob Chemother"},{"key":"R29-12-20210317","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1093\/jac\/dkf066","article-title":"Penetration of linezolid into bone, fat, muscle and haematoma of patients undergoing routine hip replacement.","volume":"50","author":"Lovering","year":"2002","journal-title":"J Antimicrob Chemother"},{"key":"R30-12-20210317","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/S0196-6553(99)70031-3","article-title":"System report, data summary from January 1990-May 1999, issued June 1999.","volume":"27","year":"1999","journal-title":"Am J Infect Control"},{"key":"R31-12-20210317","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1086\/646432","article-title":"Methicillin-resistant Staphylococcus aureus in U.S. hospitals, 1975-1991.","volume":"13","author":"Panlilio","year":"1992","journal-title":"Infect Control Hosp Epidemiol"},{"key":"R32-12-20210317","doi-asserted-by":"crossref","first-page":"417","DOI":"10.5435\/00124635-200510000-00006","article-title":"Chronic posttraumatic osteomyelitis and infected nonunion of the tibia: current management concepts.","volume":"13","author":"Patzakis","year":"2005","journal-title":"J Am Acad Orthop Surg"},{"key":"R33-12-20210317","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1016\/S0140-6736(05)79166-2","article-title":"First clinical isolate of vancomycin-intermediate Staphylococcus aureus in a French hospital.","volume":"351","author":"Ploy","year":"1998","journal-title":"Lancet"},{"key":"R34-12-20210317","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1345\/aph.16425","article-title":"Red man syndrome.","volume":"32","author":"Polk","year":"1998","journal-title":"Ann Pharmacother"},{"key":"R35-12-20210317","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1093\/jac\/dkf207","article-title":"Linezolid penetration into osteo-articular tissues.","volume":"50","author":"Rana","year":"2002","journal-title":"J Antimicrob Chemother"},{"key":"R36-12-20210317","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1097\/01.blo.0000144860.11193.5e","article-title":"Successful treatment of chronic bone and joint infections with oral linezolid.","volume":"427","author":"Rao","year":"2004","journal-title":"Clin Orthop Relat Res"},{"key":"R37-12-20210317","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1086\/382356","article-title":"Similar hematologic effects of long-term linezolid and vancomycin therapy in a prospective observational study of patients with orthopedic infections.","volume":"38","author":"Rao","year":"2004","journal-title":"Clin Infect Dis"},{"key":"R38-12-20210317","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1007\/s15010-004-3029-9","article-title":"Linezolid in the treatment of osteomyelitis: results of compassionate use experience.","volume":"32","author":"Rayner","year":"2004","journal-title":"Infection"},{"key":"R39-12-20210317","doi-asserted-by":"crossref","first-page":"147","DOI":"10.3201\/eid0501.990118","article-title":"Staphylococcus aureus with reduced susceptibility to vancomycin isolated from a patient with fatal bacteremia.","volume":"5","author":"Rotun","year":"1999","journal-title":"Emerg Infect Dis"},{"key":"R40-12-20210317","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1056\/NEJM199902183400704","article-title":"The development of vancomycin resistance in a patient with methicillin-resistant Staphylococcus aureus infection.","volume":"340","author":"Sieradzki","year":"1999","journal-title":"N Engl J Med"},{"key":"R41-12-20210317","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1592\/phco.19.3.240.30912","article-title":"Vancomycin-induced neutropenia associated with fever: similarities between two immune-mediated drug reactions.","volume":"19","author":"Smith","year":"1999","journal-title":"Pharmacotherapy"},{"key":"R42-12-20210317","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1056\/NEJM199902183400701","article-title":"Emergence of vancomycin resistance in Staphylococcus aureus: Glycopeptide-Intermediate Staphylococcus aureus Working Group.","volume":"340","author":"Smith","year":"1999","journal-title":"N Engl J Med"},{"key":"R43-12-20210317","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.2165\/00003088-200342130-00004","article-title":"Clinical pharmacokinetics of linezolid, a novel oxazolidinone antibacterial.","volume":"42","author":"Stalker","year":"2003","journal-title":"Clin Pharmacokinet"},{"key":"R44-12-20210317","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1097\/00007611-200194030-00018","article-title":"Vancomycin-resistant Enterococcus faecium osteomyelitis: successful treatment with quinupristin-dalfopristin.","volume":"94","author":"Summers","year":"2001","journal-title":"South Med J"},{"key":"R45-12-20210317","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1097\/01.qco.0000171923.62699.0c","article-title":"Vancomycin-resistant staphylococci and enterococci: epidemiology and control.","volume":"18","author":"Tenover","year":"2005","journal-title":"Curr Opin Infect Dis"},{"key":"R46-12-20210317","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1086\/340265","article-title":"Linezolid treatment for osteomyelitis due to vancomycin-resistant Enterococcus faecium.","volume":"34","author":"Till","year":"2002","journal-title":"Clin Infect Dis"}],"container-title":["Clinical Orthopaedics &amp; Related Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00003086-200708000-00012","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T16:40:43Z","timestamp":1786034443000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00003086-200708000-00012"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,8]]},"references-count":45,"URL":"https:\/\/doi.org\/10.1097\/blo.0b013e3180986d60","relation":{},"ISSN":["0009-921X"],"issn-type":[{"value":"0009-921X","type":"print"}],"subject":[],"published":{"date-parts":[[2007,8]]}}}